In humans, serum FGF21 levels are elevated in the early phase of patients with nonalcoholic fatty liver disease (NAFLD) and positively correlates with gamma-glutamyl transpeptidase (GGT)10. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.